Psychedelic Participant Advocacy Network - PsyPAN

What Psychedelic Participant Advocacy Network - PsyPAN does

Psychedelic Participant Advocacy Network (PsyPAN) is a UK-registered non-profit founded in 2021 by Ian Roullier and Leonie Schneider, both of whom participated in landmark psilocybin-for-depression clinical trials at Imperial College London and King's College London. Operating from Covent Garden, London, with one to ten staff, the organisation markets itself as the first global advocacy network dedicated to participants of psychedelic clinical trials and legal treatment centres, aggregating lived experience to influence sector practice, policy, and provider conduct.

PsyPAN delivers a four-service portfolio to two customer sets: individuals who have taken part in psychedelic clinical trials or treatment at legal centres, and the clinical trial operators and retreat/treatment centres that serve them. The Network is a community platform connecting participants via online communities, sharing circles, and integration groups. The Consultancy service deploys founders and selected members as 'Experts By Experience' to advise operators on screening, session environment, practitioner training, and aftercare. PsyPAN Accreditation is a formal assessment and certification programme auditing treatment processes with emphasis on participant feedback. Advocacy support spans both individual participants needing protection and organisations seeking to improve treatment processes.

PsyPAN monetises through quote-based consultancy engagements and accreditation application and assessment fees; pricing is not publicly disclosed. The organisation supplements fee income with profile-driven awareness campaigns, having been featured in 'The Me You Can't See', BBC's 'Depression And Me', and Michael Pollan's 'How To Change Your Mind'. Distribution is direct: outreach to enterprise clinical trial and treatment organisations for consultancy and accreditation, and a self-serve website sign-up funnel for participants joining The Network. Strategic partnerships with Imperial College London's Psychedelic Research Centre, King's College London's PsiDeR trial (steering committee), Drug Science's Medical Psychedelic Working Group, the Synthesis Institute, Alalaho, and MyDelica extend reach into UK research, policy, retreat operations, and consumer tooling without internal headcount expansion.

Name

Psychedelic Participant Advocacy Network - PsyPAN

Legal name

Psychedelic Participant Advocacy Network

Website

https://psypanglobal.org

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

PsyPAN is a London-based non-profit founded in 2021 that aggregates lived experience of psychedelic clinical trial and treatment participants to deliver consultancy, accreditation, advocacy, and community network services to global trial operators, retreat centres, and individual participants.

Ownership category

akta.pro rank

Product category

Psychedelic Participant Advocacy Services

NAICS

Other Individual and Family Services (624190), Individual and Family Services (6241), Social Assistance (624)

SIC

Services-Social Services (8300), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Mental Health & Crisis Support Services (BPAGACAD)

akta.pro secondary industries

Peer Support, Recovery Coaching & Sober Living Services (HLAFACAN), Substance Use Disorder Prevention & Recovery Services (BPAGACAE)

Keywords

• Psychedelic participant advocacy
• Clinical trial consultancy
• Treatment centre accreditation
• Peer support community
• Participant safety services

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel

Revenue model

1. Consultancy Services: PsyPAN provides tailored consultancy services to clinical trial and treatment center organizations, helping them develop and maintain best practice throughout the treatment process from screening through to aftercare. Fees are quote-based and likely project or retainer-based.
2. Accreditation Services: Clinical trial and psychedelic treatment centers can apply for PsyPAN Accreditation, which involves monitoring and assessment of treatment processes and gathering participant feedback. Organizations that meet standards receive PsyPAN Accreditation, generating revenue through the application and assessment process.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

PsyPAN provides consultancy and accreditation services to psychedelic clinical trial organizations and treatment centers, helping them develop best practices for participant safety across screening, treatment, and aftercare. The organization also delivers tailored advocacy services and operates a participant network that facilitates peer support, sharing circles, and integration groups for individuals who have participated in psychedelic clinical trials or received psychedelic-assisted therapy.

Product overview

PsyPAN is a non-profit organisation offering a portfolio of services to improve participant safety and wellbeing in the psychedelic sector. The core offerings consist of Consultancy Services (expert-by-experience guidance for organisations), PsyPAN Accreditation (formal assessment and certification for clinical trial and treatment centres), Advocacy Services (support for both organisations and individual participants), and The Network (a community platform for peer support and connection). These services work together to build best practice across the global psychedelic sector.

Differentiator

Problem solved

Functional benefit

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Imperial College London (Psychedelic Research Centre)coreStrategic or Co-development Partner · 1 January 2021Founders Ian Roullier and Leonie Schneider both participated in Imperial College London's psilocybin for depression clinical trials. The organization maintains connections to the research center for expertise and credibility in the psychedelic medicine field. Ian participated in the 2015 pilot study and Leonie in the PsiloDep 2 trial in November 2019.
• Synthesis InstitutecoreStrategic or Co-development Partner · 1 January 2021Both founders are involved with the Synthesis Institute's Connectedness Program, which focuses on nature connectedness and peer support via workshops and sharing circles. Leonie Schneider serves as a Participant Steering Group Representative shaping the development of this group-based psychedelic therapy model.
• Drug Science (Medical Psychedelic Working Group)coreStrategic or Co-development Partner · 1 January 2021Leonie Schneider represents patient interests as an Expert by Experience on Professor David Nutt's Drug Science Medical Psychedelic Working Group, which is shaping the medical and legal context in the UK for safe access to psychedelic medicine.
• AlalahominorStrategic or Co-development Partner · 1 January 2021Leonie Schneider supports the development and operational delivery of world class psychedelic retreats in the Netherlands with Alalaho (formerly the Psychedelic Society Experience Retreats), contributing expertise in participant safety and treatment best practices.
• MyDelicaminorStrategic or Co-development Partner · 1 January 2021Leonie Schneider contributes as a Friends Advisory Group member to MyDelica, which offers a progress tracker and evidence-based advice service for educating and safeguarding psychedelic journeys.
• King's College LondoncoreStrategic or Co-development Partner · 1 January 2019Ian Roullier participated in COMPASS Pathways' psilocybin clinical development programme trial run by King's College London in late 2019. Ian serves on the steering committee of King's College London's PsiDeR (Psilocybin in Depression Resistant to Standard Treatments) trial, contributing participant expertise to trial development.

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Drug Policy Alliance: Large US-based drug policy reform nonprofit. While operating at a much broader scope than psychedelics, it is comparable as a high-influence advocacy organization that shapes public, regulatory, and legislative discourse on controlled substances, including psychedelics relevant to PsyPAN's constituency.
• Harm Reduction International: International nonprofit dedicated to promoting harm reduction policies and practices for people who use drugs. Comparable to PsyPAN as a values-aligned advocacy and participant-safety nonprofit working with people engaged in controlled substance use, including psychedelics.

Direct peers

• MAPS (Multidisciplinary Association for Psychedelic Studies): Long-established nonprofit advancing psychedelic research, education, and policy advocacy. MAPS is comparable to PsyPAN because both operate as mission-driven organizations focused on legitimizing psychedelics and supporting participant/patient communities, though MAPS is much larger and also runs sponsored drug development.
• Chacruna Institute: Nonprofit that promotes psychedelic research, education, and inclusion of diverse voices in psychedelic conversations. Chacruna is comparable to PsyPAN as a values-led psychedelic advocacy and education organization with a similar community-building orientation.
• Usona Institute: Nonprofit medical research organization sponsoring psilocybin research and open-science initiatives. Usona is comparable to PsyPAN as a mission-driven, donor-funded organization operating in psychedelic medicine with participant-relevant activities.
• Beckley Foundation: UK-based psychedelic research and policy nonprofit advancing scientific study and global drug policy reform. Beckley is comparable to PsyPAN as a psychedelic-focused nonprofit working at the intersection of research, advocacy, and policy.
• Drug Science: UK-based independent scientific drug policy nonprofit that hosts the Medical Psychedelic Working Group where PsyPAN's co-founder Leonie Schneider serves. Drug Science is comparable as a psychedelic-policy and education nonprofit engaged in shaping UK medical and legal frameworks for psychedelic access.

Others

• Mind Medicine (MindMed): Public clinical-stage psychedelic medicine company developing psychedelic-assisted therapies. Comparable as an upstream sponsor whose trial and treatment ecosystems generate demand for PsyPAN's participant-advocacy services, though structured as a commercial biopharma.
• COMPASS Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Comparable as the principal trial sponsor whose participants form much of PsyPAN's addressable constituency, but operating as a commercial drug developer rather than an advocacy nonprofit.

Emerging players

• Synthesis Institute: Psychedelic therapy education and retreat organization where PsyPAN co-founders have formal roles. Comparable as an organization building participant-facing psychedelic programs and standards, partially overlapping with PsyPAN's consultancy and peer-support scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/psypanglobal
• Facebookfacebook.com/psypanglobal
• Instagraminstagram.com/psypanglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psychedelic Participant Advocacy Network - PsyPAN